Prostate CancerPhase 3NCT00004124
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
A Phase 3 study testing bicalutamide, goserelin and mitoxantrone hydrochloride in people with Prostate Cancer, run by SWOG Cancer Research Network at 234 sites in United States.
Trial summary
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Read more about this study
- Who is it for?
- Ages 18 to 120 years, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- bicalutamide, goserelin and mitoxantrone hydrochloride
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 983 participants
- Where
- 234 sitesUnited States
- Study dates
- 15 Oct 1999to 1 May 2018
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- Men only
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed stage T1-T3 adenocarcinoma of the prostate before radical prostatectomy and lymph node dissection
- Must have undergone prostatectomy within the past 120 days
- Must meet at least 1 of the following pathologic criteria:
- Gleason sum at least 8
- pT3b (seminal vesicle), pT4, or N1
- Gleason sum of 7 and positive margin
- Preoperative PSA greater than 15 ng/mL, Gleason score greater than 7, or PSA level greater than 10 ng/mL and Gleason score greater than 6
- Must have an undetectable PSA (no greater than 0.2 ng/mL) documented after surgery or prior to adjuvant hormonal therapy (for patients initiating adjuvant hormonal therapy prior to study)
- No evidence of metastatic disease on bone scan if PSA is 20 ng/mL or greater at clinical diagnosis
- No distant metastatic disease
PATIENT CHARACTERISTICS:
Performance status:
- SWOG 0-1
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Cardiovascular:
- No uncontrolled congestive heart failure
- If history of cardiac disease, LVEF at least 50% by MUGA scan or 2-D echocardiogram
Other:
- No HIV positivity
- No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer that is currently in complete remission
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- Prior neoadjuvant hormonal therapy of no more than 4 months duration before radical prostatectomy allowed
- Other concurrent adjuvant hormonal therapy allowed if initiated prior to study
- Concurrent low-dose megestrol (less than 40 mg/day) for hot flashes allowed
Radiotherapy:
- No prior radiotherapy
- No concurrent whole pelvis irradiation
- Concurrent radiotherapy allowed at the discretion of the physician
Surgery:
- See Disease Characteristics
- See Endocrine therapy
- Recovered from prior surgery
Other:
- No other prior or concurrent therapy for adenocarcinoma of the prostate
Trial locations and contacts
234 sites in 1 country.
234 sites in 1 country
United States234 sites
Cancer Care Institute of Carolina at Aiken Regional Medical Centers
Aiken, South Carolina, 29801
Akron City Hospital
Akron, Ohio, 44309-2090
University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico, 87131-5636
Study site
Alexandria, Minnesota, 56308
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
McFarland Clinic, PC
Ames, Iowa, 50010
Alaska Regional Hospital Cancer Center
Anchorage, Alaska, 99508
Providence Cancer Center
Anchorage, Alaska, 99508
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0942
Fox Valley Hematology and Oncology - East Grant Street
Appleton, Wisconsin, 54911-3496
MBCCOP - Medical College of Georgia Cancer Center
Augusta, Georgia, 30912
Rush-Copley Cancer Care Center
Aurora, Illinois, 60507
Good Shepherd Hospital
Barrington, Illinois, 60010
St. Joseph Cancer Center
Bellingham, Washington, 98225
St. Charles Medical Center - Bend
Bend, Oregon, 97701
Alta Bates Comprehensive Cancer Center
Berkeley, California, 94704
Mountainview Medical
Berlin Corners, Vermont, 05602
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
St. Vincent Healthcare
Billings, Montana, 59101
Billings Clinic Cancer Center
Billings, Montana, 59107-5100
Deaconess Billings Clinic - Downtown
Billings, Montana, 59107-7000
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Cancer Care Center at Medcenter One Hospital
Bismarck, North Dakota, 58501
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
St. Alexius Medical Center
Bismarck, North Dakota, 58502
Cancer Research Center at Boston Medical Center
Boston, Massachusetts, 02118
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Brainerd Medical Center
Brainerd, Minnesota, 56401
St. Joseph's Medical Center
Brainerd, Minnesota, 56401
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Veterans Affairs Medical Center - Brooklyn
Brooklyn, New York, 11209
Community Hospitals and Wellness Centers - Bryan
Bryan, Ohio, 43506
Veterans Affairs Medical Center - Buffalo
Buffalo, New York, 14215
Peninsula Medical Center
Burlingame, California, 94010
Lahey Clinic Medical Center - Burlington
Burlington, Massachusetts, 01805
Fletcher Allen Health Care - University Health Center Campus
Burlington, Vermont, 05401
St. James Community Hospital
Butte, Montana, 59701
Saint Francis Medical Center
Cape Girardeau, Missouri, 63701
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Cape Girardeau, Missouri, 63701
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Roper St. Francis Cancer Center at Roper Hospital
Charleston, South Carolina, 29401
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, 60611-3013
Hematology and Oncology Associates
Chicago, Illinois, 60611
Veterans Affairs Medical Center - Lakeside Chicago
Chicago, Illinois, 60611
University of Illinois Cancer Center
Chicago, Illinois, 60612-7243
Veterans Affairs Medical Center - Chicago Westside Hospital
Chicago, Illinois, 60612
Mercy Hospital and Medical Center
Chicago, Illinois, 60616
Swedish Covenant Hospital
Chicago, Illinois, 60625
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
Creticos Cancer Center at Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Memorial Hospital
Colorado Springs, Colorado, 80909
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Advocate Good Samaritan Hospital
Downers Grove, Illinois, 60515
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Evanston Northwestern Healthcare - Evanston Hospital
Evanston, Illinois, 60201-1781
Oncology/Hematology Associates of Southwest Indiana at St. Mary's Cancer Center
Evansville, Indiana, 47714
Study site
Fergus Falls, Minnesota, 56537
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Banner Thunderbird Medical Center
Glendale, Arizona, 85306
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Spectrum Health Hospital - Butterworth Campus
Grand Rapids, Michigan, 49503
Metro Health Hospital
Grand Rapids, Michigan, 49506
Great Falls Clinic
Great Falls, Montana, 59405
Sletten Regional Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
Study site
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology, Limited at St. Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
California Cancer Care, Incorporated
Greenbrae, California, 94904
Marin Cancer Institute at Marin General Hospital
Greenbrae, California, 94904
Sutter Health - Western Division Cancer Research Group
Greenbrae, California, 94904
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, 08690
PinnacleHealth Regional Cancer Center at Polyclinic Hospital
Harrisburg, Pennsylvania, 17105
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Veterans Affairs Medical Center - Hines
Hines, Illinois, 60141
Holland Community Hospital
Holland, Michigan, 49423
Tripler Army Medical Center
Honolulu, Hawaii, 96859
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio, 44131
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5289
Green Bay Oncology, Limited - Iron Mountain
Iron Mountain, Michigan, 49801
Foote Hospital
Jackson, Michigan, 49201
Midwest Center for Hematology/Oncology
Joliet, Illinois, 60432
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, 60435
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Veterans Affairs Medical Center - Kansas City
Kansas City, Kansas, 64128
CCOP - Kansas City
Kansas City, Missouri, 64131
Good Samaritan Cancer Center at Good Samaritan Hospital
Kearney, Nebraska, 68848-1990
Kingsbury Center for Cancer Care at Cheshire Medical Center
Keene, New Hampshire, 03431
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Lenoir Memorial Cancer Center
Kinston, North Carolina, 28501
La Grange Memorial Hospital
La Grange, Illinois, 60525
Lakes Region General Hospital
Laconia, New Hampshire, 03246
Sparrow Regional Cancer Center
Lansing, Michigan, 48909
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756-0002
Markey Cancer Center at University of Kentucky Chandler Medical Center
Lexington, Kentucky, 40536-0293
Southwest Medical Center
Liberal, Kansas, 67901
North Shore Oncology and Hematology Associates, Limited - Libertyville
Libertyville, Illinois, 60048
St. Rita's Medical Center
Lima, Ohio, 45801
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
McKee Medical Center
Loveland, Colorado, 80539
Dean Medical Center - Madison
Madison, Wisconsin, 53717
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
Elliot Regional Cancer Center at Elliot Hospital
Manchester, New Hampshire, 03103
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Community Medical Center
Missoula, Montana, 59801
Guardian Oncology and Center for Wellness
Missoula, Montana, 59804
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Louisiana State University Health Sciences Center - Monroe
Monroe, Louisiana, 71210
Mountainside Hospital Cancer Center
Montclair, New Jersey, 07042
Chippewa County - Montevideo Hospital
Montevideo, Minnesota, 56265
Carol G. Simon Cancer Center at Morristown Memorial Hospital
Morristown, New Jersey, 07962
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Skagit Valley Hospital Cancer Care Center
Mount Vernon, Washington, 98273
Hackley Hospital
Muskegon, Michigan, 49442
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08903
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
Cancer Care and Hematology Specialists of Chicagoland - Niles
Niles, Illinois, 60714
Mid-Illinois Hematology-Oncology Associates at Community Cancer Center
Normal, Illinois, 61761
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, 06360
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
OU Cancer Institute
Oklahoma City, Oklahoma, 73104
Cancer Care Center at Advocate Lutheran Hospital
Park Ridge, Illinois, 60068
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Northern Michigan Hospital
Petoskey, Michigan, 49770
Banner Good Samaritan Medical Center
Phoenix, Arizona, 85006
CCOP - Western Regional, Arizona
Phoenix, Arizona, 85006
Hillman Cancer Center at University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232
Mercy Regional Cancer Center at Mercy Hospital
Port Huron, Michigan, 48060
Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center
Portland, Oregon, 97210
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Legacy Emanuel Hospital and Health Center & Children's Hospital
Portland, Oregon, 97227
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Frisbie Memorial Hospital
Rochester, New Hampshire, 03867
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, 48073
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Seton Cancer Institute - Saginaw
Saginaw, Michigan, 48601
CentraCare Clinic - River Campus
Saint Cloud, Minnesota, 56303
Coborn Cancer Center
Saint Cloud, Minnesota, 56303
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67042
Naval Medical Center - San Diego
San Diego, California, 92134
San Francisco General Hospital Medical Center
San Francisco, California, 94110
UCSF Comprehensive Cancer Center
San Francisco, California, 94115
California Pacific Medical Center - California Campus
San Francisco, California, 94118
Veterans Affairs Medical Center - San Francisco
San Francisco, California, 94121
Cancer Center of Santa Barbara
Santa Barbara, California, 93105
Sansum Medical Clinic
Santa Barbara, California, 93105
Santa Barbara Hematology Oncology Medical Group at Cancer Center of Santa Barbara
Santa Barbara, California, 93105
Adult and Pediatric Urology, P.L.L.P.
Sartell, Minnesota, 56377
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98104
Harborview Medical Center
Seattle, Washington, 98104
Minor and James Medical, PLLC
Seattle, Washington, 98104
Group Health Central Hospital
Seattle, Washington, 98112
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, 98122-4307
Polyclinic First Hill
Seattle, Washington, 98122
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195-6043
North Puget Oncology at United General Hospital
Sedro-Woolley, Washington, 98284
Welch Cancer Center at Sheridan Memorial Hospital
Sheridan, Wyoming, 82801
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71101
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
Shreveport, Louisiana, 71130-3932
Hematology Oncology Associates - Skokie
Skokie, Illinois, 60076
Hematology/Oncology of the North Shore at Gross Point Medical Center
Skokie, Illinois, 60076
Santa Barbara Hematology Oncology - Solvang
Solvang, California, 93463
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
Rockwood Clinic Cancer Treatment Center
Spokane, Washington, 99204-2967
Highlands Oncology Group - Springdale
Springdale, Arkansas, 72764
Siteman Cancer Center at Barnes-Jewish Hospital
St Louis, Missouri, 63110
Missouri Baptist Cancer Center
St Louis, Missouri, 63131
Arch Medical Services, Incorporated at Center for Cancer Care Research
St Louis, Missouri, 63141
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
David C. Pratt Cancer Center at St. John's Mercy
St Louis, Missouri, 63141
Carl and Dorothy Bennett Cancer Center at Stamford Hospital
Stamford, Connecticut, 06904
Green Bay Oncology, Limited - Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235
Madigan Army Medical Center - Tacoma
Tacoma, Washington, 98431
Munson Medical Center
Traverse City, Michigan, 49684
Legacy Meridian Park Hospital
Tualatin, Oregon, 97062
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois, 61801
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Sutter Solano Medical Center
Vallejo, California, 94589
Southwest Washington Medical Center Cancer Center
Vancouver, Washington, 98668
St. John Macomb Hospital
Warren, Michigan, 48093
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
Cedar Valley Medical Specialists, PC - West Ridgeway Avenue
Waterloo, Iowa, 50702
Covenant Cancer Treatment Center
Waterloo, Iowa, 50702
University of Wisconcin Cancer Center at Aspirus Wausau Hospital
Wausau, Wisconsin, 54401
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Wenatchee Valley Medical Center
Wenatchee, Washington, 98801-2028
Associates in Womens Health, PA - North Review
Wichita, Kansas, 67203
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Wesley Medical Center
Wichita, Kansas, 67214
Cancer Center of Kansas, PA - Winfield
Winfield, Kansas, 67156
Cleveland Clinic - Wooster
Wooster, Ohio, 44691
Commonwealth Hematology-Oncology P.C. - Worcester
Worcester, Massachusetts, 01605
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Yakima, Washington, 98902
Tod Children's Hospital - Forum Health
Youngstown, Ohio, 44501
About this study
Official title: Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High-Risk Prostate Cancer Patients Following Radical Prostatectomy
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy plus mitoxantrone and prednisone is more effective than hormone therapy alone for prostate cancer.
PURPOSE: This randomized phase III trial is studying hormone therapy, mitoxantrone, and prednisone to see how well they work compared to hormone therapy alone in treating patients who have undergone radical prostatectomy for prostate cancer.
Read the detailed description
OBJECTIVES:
- Compare the overall and disease-free survival of patients with high-risk adenocarcinoma of the prostate treated with adjuvant androgen deprivation therapy with or without mitoxantrone and prednisone after radical prostatectomy.
- Compare the qualitative and quantitative toxic effects of these regimens in this patient population.
- Compare the prostate-specific antigen (PSA) progression-free survival rate in patient treated with these regimens.
- Determine whether PSA progression is a surrogate endpoint for survival or disease-free survival in this patient population.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to surgical extent of disease (organ confined vs not organ confined, but N0 vs N1), Gleason's sum (less than 7 vs 7 vs greater than 7), and planned radiotherapy (yes vs no). Patients are randomized to one of two treatment arms.
- Arm I:Patients receive goserelin subcutaneously once every 13 weeks (8 injections total) and oral bicalutamide once daily for 2 years in the absence of disease progression or unacceptable toxicity.
- Arm II:Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive hormonal therapy as in arm I beginning concurrently with the initiation of mitoxantrone and prednisone.
Patients may undergo radiotherapy 5 days a week for 6.5-7.8 weeks beginning anytime (arm I) or after completion of chemotherapy (arm II), at the discretion of the physician, in the absence of disease progression or unacceptable toxicity.
Patients are offered the possibility to participate in biomarker research by allowing their tissue/blood to be studied.
Patients are followed every 6 months for 2 years and then annually for up to 13 years.
PROJECTED ACCRUAL: A total of 1,360 patients (680 per treatment arm) will be accrued for this study within 9.5 years.
- Conditions
- Prostate Cancer
- Being tested
- bicalutamide, goserelin, mitoxantrone hydrochloride, prednisone
- Keywords
- adenocarcinoma of the prostate, stage I prostate cancer, stage II prostate cancer, stage III prostate cancer
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bicalutamideDrug
Also called Casodex
goserelinDrug
Also called Zoladex
mitoxantrone hydrochlorideDrug
prednisoneDrug
| Study group | Role | What they receive |
|---|---|---|
| bicalutamide, goserelin | Active comparator | androgen deprivation Receives: Drug: bicalutamide; Drug: goserelin |
| bicalutamide, goserelin, mitoxantrone, prednisone | Experimental | androgen deprivation plus mitoxantrone, prednisone Receives: Drug: bicalutamide; Drug: goserelin; Drug: mitoxantrone hydrochloride; Drug: prednisone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Measured from date of randomization to date of death from any cause. Patient known to be alive are censored at date of last contact.
Measured: at 10 Years
Disease Free Survival
Measured from date of randomization to date of first observation of recurrence or death due to any cause. Patients without recurrence are censored at date of last contact.
Measured: at 10 Years
Secondary outcomes (3)
Compare Qualitative and Quantitative Toxicities of These Regimens in These Patients
Number of patients with adverse events that are related to study drug
Measured: Up to 22 months from registration
PSA Progression Free Survival
Measured from date of randomization to date of PSA progression or death due to any cause. PSA progression is defined as a serum PSA level of > 0.2 ng/mL measured on 3 consecutive occasions or in the absence of increasing PSA, a positive bone scan result or other radiographic or histologic evidence of progression will be used. Date of progression will be the date that the first measure of increasing PSA is noted in the series of 3.
Measured: Up to 10 Years
PSA Progression as Surrogate Endpoint for Overall Survival or Disease Free Survival
Measured: Up to 10 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study start15 Oct 1999
- Primary completion12 Aug 2017
- Study completion1 May 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 983 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), Cancer and Leukemia Group B
- Responsible party
- Sponsor
- Investigators
- L. Michael Glode, MD, Study chair, University of Colorado, DenverNancy A. Dawson, MD, Study chair, University of Maryland Greenebaum Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00004124
- Sponsor's protocol ID
- CDR0000067352
- Other IDs
- S9921, CALGB-99904, U10CA032102
- Status last verified
- Dec 2022
- First submitted
- 10 Dec 1999
- Last updated
- 30 Dec 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Glode LM, Tangen CM, Hussain MH, et al.: Southwest Oncology Group S9921: prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. [Abstract] J Clin Oncol 27 (Suppl 15): A-5009, 2009.
Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glode LM; Southwest Oncology Group. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008 Mar 20;26(9):1532-6. doi: 10.1200/JCO.2007.13.4197.
PubMed 18349405Glode LM, Hussain MH, Benson MC, et al.: SWOG 9921: a phase III multi-institutional trial of adjuvant therapy for high risk prostate cancer after radical prostatectomy. [Abstract] American Society of Clinical Oncology 2007 Prostate Cancer Symposium, 22-24 February 2007, Orlando, FL. A-349, 2007.
Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6.
PubMed 29624463Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20;29(15):2040-5. doi: 10.1200/JCO.2010.32.2776. Epub 2011 Apr 18.
PubMed 21502546
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High-Risk Prostate Cancer Patients Following Radical Prostatectomy
- ClinicalTrials.gov ID
- NCT00004124
- Acronym / sponsor ID
- CDR0000067352
- Conditions
- Prostate Cancer
- Keywords
- adenocarcinoma of the prostate, stage I prostate cancer, stage II prostate cancer, stage III prostate cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 983 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI), Cancer and Leukemia Group B
- Study start
- 15 Oct 1999 (actual)
- Primary completion
- 12 Aug 2017 (actual)
- Study completion
- 1 May 2018 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Posted 4 Sep 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy plus mitoxantrone and prednisone is more effective than hormone therapy alone for prostate cancer.
PURPOSE: This randomized phase III trial is studying hormone therapy, mitoxantrone, and prednisone to see how well they work compared to hormone therapy alone in treating patients who have undergone radical prostatectomy for prostate cancer.
Detailed description
OBJECTIVES:
- Compare the overall and disease-free survival of patients with high-risk adenocarcinoma of the prostate treated with adjuvant androgen deprivation therapy with or without mitoxantrone and prednisone after radical prostatectomy.
- Compare the qualitative and quantitative toxic effects of these regimens in this patient population.
- Compare the prostate-specific antigen (PSA) progression-free survival rate in patient treated with these regimens.
- Determine whether PSA progression is a surrogate endpoint for survival or disease-free survival in this patient population.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to surgical extent of disease (organ confined vs not organ confined, but N0 vs N1), Gleason's sum (less than 7 vs 7 vs greater than 7), and planned radiotherapy (yes vs no). Patients are randomized to one of two treatment arms.
- Arm I:Patients receive goserelin subcutaneously once every 13 weeks (8 injections total) and oral bicalutamide once daily for 2 years in the absence of disease progression or unacceptable toxicity.
- Arm II:Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive hormonal therapy as in arm I beginning concurrently with the initiation of mitoxantrone and prednisone.
Patients may undergo radiotherapy 5 days a week for 6.5-7.8 weeks beginning anytime (arm I) or after completion of chemotherapy (arm II), at the discretion of the physician, in the absence of disease progression or unacceptable toxicity.
Patients are offered the possibility to participate in biomarker research by allowing their tissue/blood to be studied.
Patients are followed every 6 months for 2 years and then annually for up to 13 years.
PROJECTED ACCRUAL: A total of 1,360 patients (680 per treatment arm) will be accrued for this study within 9.5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| bicalutamide, goserelin | Active comparator | Drug: bicalutamide, Drug: goserelinandrogen deprivation |
| bicalutamide, goserelin, mitoxantrone, prednisone | Experimental | Drug: bicalutamide, Drug: goserelin, Drug: mitoxantrone hydrochloride, Drug: prednisoneandrogen deprivation plus mitoxantrone, prednisone |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bicalutamideAlso: Casodex | Drug | bicalutamide, goserelin, bicalutamide, goserelin, mitoxantrone, prednisone |
| goserelinAlso: Zoladex | Drug | bicalutamide, goserelin, bicalutamide, goserelin, mitoxantrone, prednisone |
| mitoxantrone hydrochloride | Drug | bicalutamide, goserelin, mitoxantrone, prednisone |
| prednisone | Drug | bicalutamide, goserelin, mitoxantrone, prednisone |
Primary outcome
Overall Survival
Time frame: at 10 Years
Measured from date of randomization to date of death from any cause. Patient known to be alive are censored at date of last contact.
Disease Free Survival
Time frame: at 10 Years
Measured from date of randomization to date of first observation of recurrence or death due to any cause. Patients without recurrence are censored at date of last contact.
3 secondary outcomes
Compare Qualitative and Quantitative Toxicities of These Regimens in These Patients
Time frame: Up to 22 months from registration
PSA Progression Free Survival
Time frame: Up to 10 Years
PSA Progression as Surrogate Endpoint for Overall Survival or Disease Free Survival
Time frame: Up to 10 Years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publicationGlode LM, Tangen CM, Hussain MH, et al.: Southwest Oncology Group S9921: prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. [Abstract] J Clin Oncol 27 (Suppl 15): A-5009, 2009.
- Results publication: PubMed 18349405Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glode LM; Southwest Oncology Group. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008 Mar 20;26(9):1532-6. doi: 10.1200/JCO.2007.13.4197.
- Results publicationGlode LM, Hussain MH, Benson MC, et al.: SWOG 9921: a phase III multi-institutional trial of adjuvant therapy for high risk prostate cancer after radical prostatectomy. [Abstract] American Society of Clinical Oncology 2007 Prostate Cancer Symposium, 22-24 February 2007, Orlando, FL. A-349, 2007.
- Derived from this study: PubMed 29624463Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6.
- Derived from this study: PubMed 21502546Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20;29(15):2040-5. doi: 10.1200/JCO.2010.32.2776. Epub 2011 Apr 18.
- SWOG Cancer Research Network websiteLink provided by the sponsor.
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
L. Michael Glode, MD study chair
University of Colorado, Denver
Nancy A. Dawson, MD study chair
University of Maryland Greenebaum Cancer Center
234 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing bicalutamide, goserelin and mitoxantrone hydrochloride in people with Prostate Cancer, run by SWOG Cancer Research Network at 234 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 234 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 Sep 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: at 10 Years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00004124, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2022.